Number of the records: 1  

Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine

  1. 1.
    SYSNO ASEP0365072
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleGenetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine
    Author(s) Mikyšková, Romana (UMG-J) RID
    Indrová, Marie (UMG-J) RID
    Šímová, Jana (UMG-J) RID
    Bieblová, Jana (UMG-J)
    Bubeník, Jan (UMG-J)
    Reiniš, Milan (UMG-J) RID
    Source TitleOncology Reports - ISSN 1021-335X
    Roč. 25, č. 6 (2011), s. 1683-1689
    Number of pages7 s.
    Languageeng - English
    CountryGR - Greece
    Keywordsgemcitabine ; human papilloma virus ; interleukin 12 ; lung metastases ; cellular vaccines ; immunotherapy
    Subject RIVEB - Genetics ; Molecular Biology
    R&D ProjectsGA301/09/1024 GA ČR - Czech Science Foundation (CSF)
    GA301/07/1410 GA ČR - Czech Science Foundation (CSF)
    CEZAV0Z50520514 - UMG-J (2005-2011)
    UT WOS000290649600027
    DOI10.3892/or.2011.1221
    AnnotationGenetically modified tumour cells producing cytokines such as IL-12 are potent activators of antitumour immune responses and a promising therapeutic modality when combined with chemotherapy. We examined whether IL-12-producing cellular vaccines can augment chemotherapy of HPV 16-associated murine tumours with cytostatic agent gemcitabine (GEM). Peritumoral administration of IL-12-producing tumour vaccines enhanced the effect of cytoreductive therapy with GEM in non-metastasizing murine carcinoma TC-1 and in metastasizing murine carcinoma MK16. Lung metastases in mice were substantially decreased. In surgical minimal residual tumour disease IL-12-producing tumour vaccine and GEM after MK16 tumour surgery also reduced tumour recurrences and metastases. Tumour inhibitory effects of GEM plus IL-12 were associated with high production of interferon-γ by splenocytes. IL-12-producing vaccine can thus enhance the effect of GEM chemotherapy in some HPV16-associated murine tumour models.
    WorkplaceInstitute of Molecular Genetics
    ContactNikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217
    Year of Publishing2012
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.